HCW Biologics (HCWB)
1.58
-0.05 (3.07%)
Upcoming Events
Latest Headlines
Form 8-K HCW Biologics Inc. For: May 29
June 1, 2026 7:30 AM - SEC Filing
HCW Biologics Inc. (HCWB) PT Raised to $5 at Maxim Group
May 28, 2026 2:34 PM - StreetInsider
Form 4 HCW Biologics Inc. For: May 22 Filed by: Wong Hing C
May 27, 2026 7:27 PM - SEC Filing
Form 4 HCW Biologics Inc. For: May 22 Filed by: GARRETT SCOTT T
May 27, 2026 7:25 PM - SEC Filing
Form 4 HCW Biologics Inc. For: May 22 Filed by: Byam Rebecca
May 27, 2026 7:24 PM - SEC Filing
Form 8-K HCW Biologics Inc. For: May 21
May 27, 2026 8:00 AM - SEC Filing
HCW Biologics regains rights to CAR-T therapy reagents from Wugen
May 27, 2026 7:45 AM - StreetInsider
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
May 27, 2026 7:45 AM - StreetInsider
HCW Biologics raises $4 million in private placement with E.F. Hutton
May 22, 2026 4:03 PM - StreetInsider
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
May 22, 2026 4:03 PM - StreetInsider
Form 8-K HCW Biologics Inc. For: May 21
May 21, 2026 4:59 PM - SEC Filing
HCW Biologics prices $4 million private placement offering
May 21, 2026 9:53 AM - StreetInsider
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
May 21, 2026 9:53 AM - Globe NewsWire
Form POS AM HCW Biologics Inc.
May 18, 2026 8:27 AM - SEC Filing
Form SCHEDULE 13G/A HCW Biologics Inc. Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:21 AM - SEC Filing
Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism
May 15, 2026 10:15 AM - StreetInsider
HCW Biologics (HCWB) Tops Q1 EPS by 37c
May 14, 2026 5:51 PM - StreetInsider
Form 10-Q HCW Biologics Inc. For: Mar 31
May 14, 2026 4:33 PM - SEC Filing
Form 8-K HCW Biologics Inc. For: May 14
May 14, 2026 4:31 PM - SEC Filing
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
May 14, 2026 4:25 PM - StreetInsider
HCW Biologics discovers drug candidate prevents lung disease in infants
May 14, 2026 7:31 AM - StreetInsider
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
May 14, 2026 7:30 AM - StreetInsider
Form POS AM HCW Biologics Inc.
May 13, 2026 4:37 PM - SEC Filing
Form 8-K HCW Biologics Inc. For: Apr 30
April 30, 2026 4:32 PM - SEC Filing
HCW Biologics adjourns special meeting due to lack of quorum
April 30, 2026 4:20 PM - StreetInsider
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
April 30, 2026 4:20 PM - StreetInsider
Form EFFECT HCW Biologics Inc.
April 30, 2026 6:16 AM - SEC Filing
Form 8-K HCW Biologics Inc. For: Apr 29
April 30, 2026 6:13 AM - SEC Filing
Form DEF 14A HCW Biologics Inc. For: Apr 28
April 29, 2026 11:25 AM - SEC Filing
Form ARS HCW Biologics Inc. For: Dec 31
April 28, 2026 5:29 PM - SEC Filing
HCW Biologics reveals mechanism for cancer T-cell engager HCW11-018b
April 27, 2026 7:30 AM - StreetInsider
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
April 27, 2026 7:30 AM - Globe NewsWire
Form S-1/A HCW Biologics Inc.
April 24, 2026 5:30 PM - SEC Filing
Form S-1 HCW Biologics Inc.
April 23, 2026 7:16 PM - SEC Filing
Form PRE 14A HCW Biologics Inc. For: Apr 17
April 17, 2026 5:24 PM - SEC Filing
Form 8-K HCW Biologics Inc. For: Apr 15
April 16, 2026 4:31 PM - SEC Filing
Form 10-K HCW Biologics Inc. For: Dec 31
March 31, 2026 5:13 PM - SEC Filing
Form 8-K HCW Biologics Inc. For: Mar 31
March 31, 2026 5:12 PM - SEC Filing
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
March 31, 2026 5:05 PM - Globe NewsWire
Form 8-K HCW Biologics Inc. For: Mar 16
March 17, 2026 8:03 AM - SEC Filing
HCW Biologics receives $7 million upfront fee for HCW11-006 license
March 17, 2026 7:51 AM - StreetInsider
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
March 17, 2026 7:50 AM - Globe NewsWire
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
March 17, 2026 7:50 AM - StreetInsider
HCW Biologics reports positive CAR-T cell therapy research results
March 16, 2026 8:04 AM - StreetInsider
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
March 16, 2026 8:00 AM - StreetInsider
Form DEF 14A HCW Biologics Inc. For: Mar 13
March 13, 2026 4:16 PM - SEC Filing
Full Article List
